Ono Pharmaceutical (OTCMKTS:OPHLF) Sets New 12-Month Low – Time to Sell?

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF)’s share price hit a new 52-week low on Wednesday . The stock traded as low as $11.64 and last traded at $11.64, with a volume of 7020 shares trading hands. The stock had previously closed at $12.70.

Ono Pharmaceutical Price Performance

The stock has a market capitalization of $5.98 billion, a P/E ratio of 6.90 and a beta of 0.55. The company has a fifty day moving average of $14.24 and a two-hundred day moving average of $14.27.

Ono Pharmaceutical (OTCMKTS:OPHLF) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.34 earnings per share for the quarter. The firm had revenue of $754.85 million during the quarter. Ono Pharmaceutical had a return on equity of 15.17% and a net margin of 24.26%. As a group, equities research analysts predict that Ono Pharmaceutical Co., Ltd. will post 1.24 EPS for the current fiscal year.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.